The company’s assay design, astronomy-grade imaging and advanced analytics, and microarray printing provides the sensitivity and reproducibility of single-plexed ELISA in a multiplexed format.

Aushon founder and CEO Pete Honkanen said scientists are satisfied with the performance of multiplex platform which can deliver in terms of overall lab productivity, reduced sample consumption and lower cost per study.

Duke Phase I Biomarker Laboratory co-director Andrew Nixon said, "The sensitivity and consistency were equivalent to or better than the singleplex ELISA results for the markers evaluated."

The company is planning for a full launch in June 2102.